1. Home
  2. TKNO vs CGTX Comparison

TKNO vs CGTX Comparison

Compare TKNO & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Teknova Inc.

TKNO

Alpha Teknova Inc.

HOLD

Current Price

$4.76

Market Cap

280.9M

Sector

Health Care

ML Signal

HOLD

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

N/A

Current Price

$1.65

Market Cap

110.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TKNO
CGTX
Founded
1996
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
280.9M
110.8M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
TKNO
CGTX
Price
$4.76
$1.65
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$3.33
AVG Volume (30 Days)
238.2K
1.3M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
43.86
62.79
EPS
N/A
N/A
Revenue
$40,520,000.00
N/A
Revenue This Year
$8.27
N/A
Revenue Next Year
$13.13
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.35
N/A
52 Week Low
$1.91
$0.29
52 Week High
$6.68
$3.83

Technical Indicators

Market Signals
Indicator
TKNO
CGTX
Relative Strength Index (RSI) 57.27 64.29
Support Level $4.79 $1.53
Resistance Level $4.94 $1.82
Average True Range (ATR) 0.47 0.13
MACD -0.00 0.04
Stochastic Oscillator 49.43 67.75

Price Performance

Historical Comparison
TKNO
CGTX

About TKNO Alpha Teknova Inc.

Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: